Eversept Partners LP Makes New Investment in Repligen Corporation $RGEN

Eversept Partners LP bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the 1st quarter, Holdings Channel reports. The firm bought 120,785 shares of the biotechnology company’s stock, valued at approximately $14,231,000. Repligen makes up 0.8% of Eversept Partners LP’s investment portfolio, making the stock its 28th biggest holding.

A number of other hedge funds have also recently modified their holdings of the business. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen in the third quarter worth approximately $368,387,000. Opti Capital Management LP bought a new position in Repligen in the 4th quarter valued at $2,399,209,000. Maverick Capital Ltd. bought a new position in Repligen in the 1st quarter valued at $178,946,000. Wasatch Advisors LP purchased a new stake in Repligen in the first quarter worth $146,513,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in Repligen in the fourth quarter worth $199,176,000. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 0.7%

Shares of Repligen stock opened at $131.06 on Tuesday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The firm has a market capitalization of $7.39 billion, a price-to-earnings ratio of 145.62, a PEG ratio of 2.54 and a beta of 1.06. The firm’s 50 day simple moving average is $132.21 and its two-hundred day simple moving average is $132.05.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company posted $0.39 earnings per share. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts predict that Repligen Corporation will post 1.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Citigroup upgraded Repligen to a “buy” rating in a report on Tuesday, July 7th. Finally, HSBC decreased their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $165.36.

Insider Transactions at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.60% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.